Accessibility Menu
Telo Genomics logo

Telo Genomics(OTC) TDSGF

Market Cap$3.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-99%
5 Year-92%
1 Year-56%
1 Month-3%
$0.03
-3.44%
-0.00Today
Telo Genomics last closing stock price
MetricPriceDate
Last closeUSD 0.032026-07-29
Telo Genomics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.24%USD 0.032026-07-20
1 month-3.17%USD 0.032026-06-26
3 month-21.56%USD 0.042026-04-22
Year to date-37.85%USD 0.052025-12-26
1 year-56.43%USD 0.072025-07-28
3 year-84.04%USD 0.192023-07-27
5 year-92.13%USD 0.392021-07-30
Since inception-99.05%USD 3.272016-11-09

Telo Genomics Financials at a Glance

Market Cap

$3.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$2.15M

EPS (TTM)

-$0.02

P/E Ratio

-1.83

Dividend

$0.00

Beta (Volatility)

-0.17 (Low)

Price

$0.03

Volume

1,348

Open

$0.03

Previous Close

$0.03

Daily Range

$0.03 - $0.03

52-Week Range

$0.02 - $0.07

Estimated Earnings Date

Jun 1, 2026

TDSGF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Telo Genomics

Telo Genomics Corp. is a biotechnology company dedicated to developing advanced predictive technologies aimed at personalizing treatment for patients with specific health challenges. The company specializes in telomere analysis, providing diagnostic and prognostic insights primarily in oncology and neurological diseases.

Products and Services
  • Telomere analysis platform for diagnostic insights
  • Telo-MM, a solution for managing Multiple Myeloma
  • TeloView, proprietary software for measuring telomere features
Growth Outlook
  • Collaborative agreement with Mayo Clinic for Telo-MM validation studies
  • Focus on expanding applications in oncology and neurological diseases
  • Potential market growth driven by increasing demand for personalized medicine
Financial Highlights
  • Recent quarterly net income of -$561,925, reflecting ongoing investment in R&D
  • Cash and cash equivalents of $977,995 as of March 31, 2026
  • Trailing twelve months (TTM) revenue of $0, indicating early-stage development
Telo Genomics Corp. operates in the medical diagnostics and research sector, focusing on innovative solutions that leverage liquid biopsies. The flagship product, Telo-MM, is designed to provide healthcare professionals with critical information for managing Multiple Myeloma, a significant area of need in cancer treatment. The company’s proprietary software, TeloView, enhances the precision of telomere measurements, further supporting personalized treatment strategies. Despite reporting a net loss in recent quarters, Telo Genomics is strategically positioned for growth through its partnership with the Mayo Clinic and a commitment to expanding its product offerings. The focus on personalized medicine aligns with broader industry trends, suggesting potential for future revenue generation as the market for tailored healthcare solutions continues to evolve. The current cash position provides a foundation for ongoing research and development efforts, essential for advancing the company's innovative technologies.
AI Generated • Jul 29, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Sabine Mai, PhD

Website

www.telodx.com

Headquarters

Toronto, ON M5G 1L7, CA

TDSGF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

902.36%

Return on Capital

-524.75%

Return on Assets

-190.86%

Earnings Yield

-54.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

100.43M

Volume

1.35K

Avg. Volume

7.04K

Financials (TTM)

Gross Profit

-CA$53.45K

Operating Income

-CA$2.07M

EBITDA

-CA$2.21M

Operating Cash Flow

-CA$1.30M

Capital Expenditure

-CA$224.82K

Free Cash Flow

-CA$1.53M

Cash & ST Invst.

CA$978.00K

Total Debt

CA$1.32M

Telo Genomics Performance Analysis

Telo Genomics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30CAD 0N/A
20232023-06-30CAD 0N/A
20242024-06-30CAD 0N/A
20252025-06-30CAD 0N/A
Telo Genomics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30N/A
Q12025-09-30N/A
Q22025-12-31N/A
Q32026-03-31N/A
Telo Genomics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30CAD -0.03N/A
20232023-06-30CAD -0.0423.2%
20242024-06-30CAD -0.03-19.7%
20252025-06-30CAD -0.02-21.0%
Telo Genomics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-3054.0%
Q12025-09-30-3.8%
Q22025-12-313.7%
Q32026-03-31-7.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$29.44K

-1371.0%

Gross Margin

0.00%

N/A

Market Cap

$3.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$387.79K

N/A

Employees

8

N/A

Net Income

-CA$561.93K

+33.5%

EBITDA

-CA$480.88K

+42.9%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$978.00K

-21.7%

Total Debt

CA$1.32M

N/A

Accounts Receivable

CA$33.68K

+10.7%

Inventory

CA$0.00

N/A

Long Term Debt

CA$83.67K

N/A

Short Term Debt

CA$1.23M

N/A

Return on Assets

-1.91%

N/A

Return on Invested Capital

2.56%

N/A

Free Cash Flow

-CA$326.45K

+67.3%

Operating Cash Flow

-CA$326.45K

+67.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TGIFF1933 Industries Inc.
$0.00+14.52%
ICBUiMD Companies, Inc.
$0.00-10.00%
SLDXStella Diagnostics Inc.
$0.01+0.00%
CLABFCore One Labs Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About TDSGF

What is the current price of Telo Genomics?

Telo Genomics is trading at $0.03 per share.

What is the 52-week range for Telo Genomics?

Over the past 52 weeks, Telo Genomics has traded between $0.02 and $0.07.

How much debt does Telo Genomics have?

As of the most recent reporting period, Telo Genomics reported total debt of CA$942.33K.

How much cash does Telo Genomics have on hand?

Telo Genomics reported CA$698.99K in cash and cash equivalents in its most recent financial results.

What is Telo Genomics’s dividend yield?

Telo Genomics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services